In this article, we will take a look at the best money-making stocks to buy right now.
In an environment marked by shifting rate expectations and growth volatility, investors remain focused on identifying companies capable of delivering sustainable earnings expansion. Stocks with strong fundamentals, resilient cash flows, and durable competitive advantages continue to stand out as potential long-term wealth compounders. For investors seeking to enhance portfolio returns, balanced exposure to fundamentally strong businesses remains important.
Disciplined investing is all the more important in uncertain times. A report by U.S. Bank’s US Wealth Management division, published on February 4, titled “Is a market correction coming?” outlines that U.S. stocks entered this year with new highs as earnings improve and strong customer spending trends compensate for tariff and government shutdown uncertainty. The publication advances by underpinning the importance of AI-powered leadership, which the firm believes has contributed significantly to the improved performance. In summary, the shift in market direction is driven by tariff discussions, implementation timelines, legal headwinds, and inflation dynamics.
This is supported by an article by Invesco, titled “Greater clarity on the main risks to the market,” that was published on February 2. The publication notes that the year began on a promising note. As stated,
With the first month of 2026 now behind us, markets largely reflect the macro environment we had expected, including sound global growth, supportive policy settings worldwide, and largely contained inflation, all of which continue to underpin stocks. So far, so good. And I’ve often heard good things about years that start with a positive January.
With that said, let’s dive into the best money-making stocks to buy right now. These companies belong to a range of sectors, including technology, consumer cyclical, and communication services.
Photo by Karolina Grabowska from Pexels
Our Methodology
In compiling the list of 11 best money-making stocks to buy right now, we used the Stock Analysis screener to identify stocks with a market capitalization exceeding $2 billion. Next, we filtered for companies with a return on equity (ROE) of over 30% and a return on invested capital (ROIC) of over 25%, as of the close on February 13. We then selected eleven companies with the highest upside potential and ranked them in ascending order. We also included data on hedge fund holdings in these companies based on Insider Monkey’s database, as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
11. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Upside Potential as of February 13, 2026: 44.88%
Number of Hedge Fund Holders: 72
On February 13, Morgan Stanley trimmed the price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $360 from $408 and reiterated an Equal Weight rating, TheFly reported. In a research note, the analyst said that although near-term pressures exist, the preannounced fourth-quarter revenue and reaffirmed 2026 TTR sales guidance reflect increased confidence in the launch.
On the same day, RBC Capital also reduced its price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $450 from $465 and maintained an Outperform rating. This downward price revision was attributed to near-term headwinds for the company. While acknowledging the company’s strong commercial execution in 2025, the firm noted that Alnylam appears to be a high-quality company capable of achieving its financial targets.
The company’s future will be supported by 80% of the 300,000 global TTR-CM patients who remain undiagnosed, a significant market opportunity that can be seized, the firm noted. With that said, RBC Capital noted that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is targeting growth beyond its TTR franchise to expand into Huntington’s disease, obesity, and HHT treatments.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a Massachusetts-based RNAi therapeutics company specializing in therapeutics based on ribonucleic acid interference. Founded in 2002, the company provides solutions for hypercholesterolemia, primary hyperoxaluria type 1, acute hepatic porphyria, and hATTR, among others.
10. CarGurus, Inc. (NASDAQ:CARG)
Upside Potential as of February 13, 2026: 48.13%
Number of Hedge Fund Holders: 31
On February 5, Needham trimmed the price target on CarGurus, Inc. (NASDAQ:CARG) to $37 from $44 and maintained a Buy rating. This comes after the analyst’s participation in the National Automobile Dealers Association’s conference, and the analyst believes that concerns about the company being replaced or bypassed are exaggerated at this time. With dealers advised to adopt AI gradually, their focus should be on local brand marketing and customer engagement tools, rather than on using AI to increase sales, the analyst asserted.
Later, on February 11, CarGurus, Inc. (NASDAQ:CARG) announced the expansion of its “Big Deal” brand campaign, featuring the company’s newly launched AI-powered innovations that simplify online research and comparison. This would allow shoppers to make a more personalized and confident decision at the dealership.
“CarGurus was founded to redefine the car shopping experience for consumers, bringing more transparency with data and technology,” stated Dafna Sarnoff, CarGurus, Inc. (NASDAQ:CARG) Chief Marketing Officer. “Now, as the No. 1 most visited car shopping site, we continue to invest in innovations that help consumers get their best deal with confidence, and enjoy the ‘big deal’ experience of finding a car you love.”
Overall, CarGurus, Inc. (NASDAQ:CARG) is a buy from slightly more than half of the analysts covering the stock, with 40% neutral and 7% bearish. With a 1-year median price target of $40.50, the stock has an upside potential 48.13%.
CarGurus, Inc. (NASDAQ:CARG) is a Massachusetts-based online automotive platform operating through two segments: U.S. Marketplace and Digital Wholesale.
